BURLINGAME, California – May 3, 2022
Harnessing AI to Unlock Breakthrough Therapies
Eli Lilly and Company and Genesis Therapeutics have entered into a groundbreaking collaboration to accelerate the discovery and development of next-generation therapeutics by harnessing the power of artificial intelligence (AI). This strategic alliance will leverage Genesis Therapeutics’ cutting-edge AI-driven molecular design platform and computational modeling to rapidly identify and optimize innovative small molecule drug candidates across key therapeutic areas.
Harnessing AI to Unlock Breakthrough Therapies
Through this partnership, Eli Lilly will integrate Genesis Therapeutics’ proprietary AI technology, which merges 3D molecular simulations with deep learning algorithms, to redefine the drug discovery process. The collaboration is poised to fast-track the identification of first-in-class and best-in-class small molecule therapeutics, addressing pressing unmet medical needs.
“At Eli Lilly, we are committed to leading the next frontier of drug discovery by embracing cutting-edge technologies,” said Eli Lilly and Company. “By partnering with Genesis Therapeutics, we can leverage AI’s transformative potential to unlock novel therapeutics faster and with greater precision, ultimately bringing life-changing treatments to patients.”
Advancing AI-Driven Drug Development at Scale
Genesis Therapeutics has built an industry-leading AI platform that fuses generative and predictive molecular modeling with scalable cloud computing. This state-of-the-art technology enables scientists to explore vast chemical spaces with unprecedented speed and accuracy, identifying promising compounds that may have been previously inaccessible through traditional discovery methods.
“Our partnership with Eli Lilly is a milestone moment in AI-driven drug discovery,” said Genesis Therapeutics’ CEO Evan Feinberg, Ph.D. “We believe that by integrating our AI-powered capabilities with Eli Lilly’s extensive expertise in pharmaceutical development, we can push the boundaries of what’s possible in medicine and deliver new therapies to patients in need.”
Strategic Collaboration Terms and Vision for the Future
Under this agreement, Genesis Therapeutics will initially collaborate with Eli Lilly on three selected drug targets and will receive an upfront payment of $20 million. Eli Lilly retains the option to expand the collaboration by adding two additional targets, each requiring a separate nomination fee. If all milestones across research, development, and commercialization are met, Genesis could receive up to $670 million in total payments. Additionally, Genesis will be entitled to royalty payments based on the net sales of successfully developed therapies.
About Genesis Therapeutics
Genesis Therapeutics is an AI-driven biotech company using its GEMS platform to design and optimize small molecule therapeutics for complex targets. Combining advanced AI, machine learning, and experimental validation, Genesis accelerates drug discovery from its headquarters in Burlingame, CA, and San Diego lab. Backed by $300M+ in funding, it is building a pipeline of breakthrough therapies.
By